[Acute bronchitis - modern possibilities of mucactive therapy]

Area of Science:

• Respiratory Medicine
• Pharmacology
• Clinical Trials

Context:

• Acute bronchitis (AB) is a common respiratory illness in adults.
• Mucoactive therapy aims to improve mucus clearance and reduce cough.
• Standard treatments include acetylcysteine, bromhexine, and other mucolytics.

Purpose:

• To compare the clinical effectiveness and safety of erdosteine versus standard mucoactive therapy in adult patients with acute bronchitis.
• To assess the impact of erdosteine on cough severity, resolution time, and patient satisfaction.
• To evaluate biochemical markers such as C-reactive protein (CRP), interleukin-6 (IL-6), and exhaled nitric oxide (NO) in relation to treatment outcomes.

Summary:

• An observational study involving 100 adult patients with AB found that erdosteine significantly reduced the duration of mucoactive therapy (5.32 days vs. 8.5 days) compared to standard treatments.
• Patients receiving erdosteine reported higher satisfaction and experienced a more pronounced reduction in cough severity by the sixth day of treatment.
• Biomarkers including CRP, IL-6, and exhaled NO levels normalized by the sixth day in both groups, suggesting viral etiology and the effectiveness of mucolytics.

Impact:

• Erdosteine offers a more efficient therapeutic option for acute bronchitis, leading to quicker symptom relief and shorter treatment durations.
• The study provides new insights into the role of CRP, IL-6, and exhaled NO in monitoring AB and assessing treatment response.
• Findings support erdosteine's significant mucoactive effect and its potential to improve patient outcomes in acute bronchitis management.